Criminal networks and indoor cannabis in Europe: has the phenomenon reached France?
Drugs, International Challenges n°1, OFDT, 4 p.
On 8 February 2011 in the Courneuve, a Paris suburb in the Seine-Saint Denis department, approximately 700 cannabis plants were discovered in a clandestine indoor plantation by the investigators of the OCRIEST (Central office on illegal immigration and employment) and the OCRTIS (Central office for the repression of drug-related offences). Although this plantation was not the first to be discovered on French territory, this case was particularly troubling for the authorities because it was an operational carbon copy of Dutch and British cannabis factories. As a result, major, fundamental concern was raised regarding the development of herbal cannabis supply. While in France cannabis tends to be supplied by small growers who produce mainly for their own personal needs, the Courneuve case begs the following question: Has organised crime penetrated French herbal cannabis production like in other countries in Europe? In order to fully understand the issues raised by this question, this article will first examine the current European cannabis market structure. Thereafter, it will discuss the situation in the main cannabis- producing European countries. Finally, it will examine the situation in France and the possible criminal risks that are taking shape.
Download the PDF file (705 Ko)
Drugs in Europe
What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2017 EMCDDA European Drug Report.
Country drug reports 2017
Developed by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.